At the American Society for Radiation Oncology (ASTRO) meeting, computer-aided detection (CAD) developer iCAD is touting clinical data supporting the use of its Xoft Axxent electronic brachytherapy (eBx) system for treating nonmelanoma skin cancer and early-stage breast cancer.
In a poster presentation describing the treatment of 827 women at 27 hospitals, researchers concluded that the Xoft system was safe for women who have early-stage breast cancer, yielding low morbidity, excellent to good cosmetic results, and a low rate of low-grade adverse events, iCAD said.
In another poster at ASTRO 2016, 96% of nonmelanoma skin cancer patients surveyed between 32 to 72 months post-treatment with Xoft eBx said they were satisfied with their clinical and cosmetic treatment outcomes, according to the vendor. The research also includes updated data for the treatment of 282 lesions in 187 patients with nonmelanoma skin cancer. The team said there were only three recurrences during the study, and good to excellent cosmesis was found in nearly all patients up to five years post-treatment.
